
ESMO 2019: Adding immunotherapy to chemotherapy prolongs progression free survival in bladder cancer
Patients with metastatic urothelial cancer have longer progression free survival when treated with first-line immunotherapy…
Patients with metastatic urothelial cancer have longer progression free survival when treated with first-line immunotherapy…